Fischer Medical Ventures Limited held its 33rd Annual General Meeting on September 29, 2026, through Video Conferencing. The meeting commenced at 11:00 am IST and concluded at 11:59 am, with sixty-one members participating remotely to approve statutory resolutions.

The company utilized the services of National Securities Depositories Limited for both the video conferencing platform and e-voting infrastructure. Mr. Ravindran Govindan, Chairman and Managing Director, presided over the session. The requisite quorum was satisfied by the attendance of the members, including a corporate member representing 50.78% of the equity share capital.

Board participation and governance

A significant portion of the board participated from international locations, reflecting the company's global operational footprint. Key managerial personnel joined from various Indian cities to address shareholder queries regarding performance and strategy.

Shareholder engagement topics

During the question-and-answer session, two speaker shareholders raised queries concerning the group's strategic direction. Management, including the Chief Operating Officer and Chief Financial Officer, responded to inquiries on several critical operational metrics.

• International operations and growth opportunities
• Standalone versus consolidated financial performance
• Research and development initiatives
• Capital allocation and strategic priorities
• Working capital management and debtor cycles
• Liabilities structure and operating cash flows
• Business guidance and competitive positioning

Mr. Nuren Lodaya, a practising company secretary, served as the scrutiniser for the remote e-voting process. The auditors' report and secretarial audit report contained no qualifications or adverse remarks, which were taken as read during the proceedings.

Fischer Medical Ventures Limited disclosed that its wholly owned material subsidiaries declared dividends for the financial year ended March 31, 2026. The combined domestic dividend payout from Time Medical International Ventures (India) Private Limited and FlynnCare Health Innovations Private Limited totals ₹16.5 crore.

The disclosures were made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filings highlight significant cash distributions from key operating units to the parent company.

Subsidiary dividend details

Time Medical International Ventures (India) Private Limited declared a dividend of ₹6.5 crore at its Annual General Meeting held on September 28, 2026. This payout relates to the financial year ended March 31, 2026.

FlynnCare Health Innovations Private Limited also held its Annual General Meeting on September 28, 2026, declaring a dividend of ₹10 crore for the same fiscal period. This represents the largest single domestic dividend contribution among the disclosed subsidiaries.

FMV Global Innovation Pte Limited, a Singapore-based subsidiary, approved an interim dividend of $1.1 million at its Board meeting on September 21, 2026. This declaration is for the year ended March 31, 2027.

What the numbers show

The aggregate dividend inflow to Fischer Medical Ventures comprises ₹16.5 crore from Indian entities and $1.1 million from the global entity. The timing of the declarations indicates that the parent company will receive these funds shortly after the respective AGMs and board meetings. The FY27 interim dividend from FMV Global suggests a forward-looking cash distribution strategy for the international arm, distinct from the retrospective FY26 payouts by the Indian subsidiaries.